derived implications from previous clinical trials and cohort studies that KRAS mutations may have a stronger effect on prognosis in patients with metastatic colorectal cancer, and discussed possible biomarkers to recognize resistance to EGFR inhibition (32). This evidence concerns the gene KRAS and metastatic colorectal cancer.